Today marks Saniona’s 10th anniversary since its founding. BioStock was visited in the studio by the company’s founder Jørgen Drejer, now Chief Scientific Officer, who talks about the transformation that the company has undergone during this decade. We also learn more about the success of the primary drug candidate Tesomet, the importance of now having a US-based management team and his view of the company’s future.
Watch the full interview with Jørgen Drejer below. Also see BioStock’s written interview with Drejer here.The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.